DermTech Announces Additional Restructuring Actions to Focus on Revenue Growth and Streamline Operations
- Ongoing emphasis on growing revenue for the DermTech Melanoma Test
- Approximately $40 million in total operating expense reductions compared to fiscal 2022 resulting from all restructuring...
Related Keywords
, Bret Christensen , Nasdaq , Dermtech Inc , Dermtech Melanoma Test , Markets ,
comparemela.com © 2020. All Rights Reserved.